Health and Financial Benefits of Averting Malaria in Zambia: An ECEA
2019
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout of the malaria vaccine RTS,S/AS01 in Zambia on the health benefits of children under five, and financial benefits on their households. The authors assumed a three-dose vaccination schedule (over 6-9 months), and vaccine cost of US$5 per dose. To assess vaccine impact, for each income quintile, they computed the number of under-five malaria deaths prevented, the household out-of-pocket (OOP) malaria-related treatment expenditure averted, and the number of cases of catastrophic health expenditure averted.
Results found that rolling out the RTS,S/AS01 vaccine in Zambia within one birth cohort would avert an estimated 670 deaths for children under five years of age, and prevent approximately US$1 million of OOP expenditure, both largely concentrated among the poorer households. Vaccination would also prevent about 4,400 associated cases of catastrophic expenditure among households in all income quintiles, with the exception of the highest. The estimated cost of the program would be US$9 million per birth cohort.
Health and Financial Benefits of Averting Malaria in Zambia: An ECEA
Source:
Liu L, Portnoy A, True Z, Fink G, Verguet S. The Health and Financial Benefits for Households from Averting Malaria with RTS,S/AS01 Vaccine in Zambia: An Extended Cost-Effectiveness Analysis. Working Paper #26. Disease Control Priorities, Third Edition 2019. http://dcp-3.org/resources/health-and-financial-benefits-households-averting-malaria-rtssas01-vaccine-zambia-extended